Payment overview · 2025
General Payments
$961.51
58 reported records · 16 companies
Healthcare provider profile · identity verified
Robert Lloyd Dickson, DO
Allopathic & Osteopathic Physicians|Family Medicine · KILLEN, AL · NPI 1982198594
Verified facts
What the public records show
CMS Open Payments records show Robert Lloyd Dickson, DO received $961.51 in general payments during 2025 across 58 reported records.
Novo Nordisk Inc accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $166.35 | 17.3% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.64 | 14.8% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.09 | 7.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.07 | 6.7% | 4 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $61.67 | 6.4% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $58.80 | 6.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.52 | 5.7% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.13 | 5.5% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $48.49 | 5.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.20 | 5.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.00 | 4.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.10 | 4.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.13 | 3.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.46 | 3.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.10 | 2.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.76 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $961.51 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $130.33 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $128.08 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.28 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $68.09 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.07 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.07 | 4 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $61.67 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $58.80 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $53.13 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $48.49 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.07 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.10 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.62 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $33.46 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.13 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.13 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $1.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 363 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
363 | 90 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
217 | 58 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 803 | 246 |
| Gabapentin | Gabapentin | 674 | 180 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 661 | 167 |
| Omeprazole | Omeprazole | 584 | 203 |
| Atorvastatin Calcium | Atorvastatin Calcium | 534 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 470 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 411 | 142 |
| Losartan Potassium | Losartan Potassium | 397 | 121 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 386 | 141 |
| Mounjaro | Tirzepatide | 363 | 90 |
| Metformin Hcl | Metformin Hcl | 359 | 115 |
| Alprazolam | Alprazolam | 357 | 78 |
| Tramadol Hcl | Tramadol Hcl | 347 | 108 |
| Zolpidem Tartrate | Zolpidem Tartrate | 337 | 77 |
| Lisinopril | Lisinopril | 313 | 109 |
| Montelukast Sodium | Montelukast Sodium | 310 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 293 | 89 |
| Furosemide | Furosemide | 287 | 99 |
| Simvastatin | Simvastatin | 252 | 88 |
| Meloxicam | Meloxicam | 250 | 86 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 243 | 73 |
| Sertraline Hcl | Sertraline Hcl | 240 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 233 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 82 |
| Trazodone Hcl | Trazodone Hcl | 232 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 226 | 62 |
| Clonazepam | Clonazepam | 221 | 43 |
| Eliquis | Apixaban | 217 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 81 |
| Potassium Chloride | Potassium Chloride | 206 | 76 |
| Pregabalin | Pregabalin | 205 | 52 |
| Allopurinol | Allopurinol | 181 | 61 |
| Celecoxib | Celecoxib | 177 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 60 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 173 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 172 | 39 |
| Spironolactone | Spironolactone | 158 | 48 |
| Metformin Hcl Er | Metformin Hcl | 152 | 55 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 150 | 59 |
| Buspirone Hcl | Buspirone Hcl | 145 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 140 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 136 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 128 | 39 |
| Lorazepam | Lorazepam | 125 | 31 |
| Carvedilol | Carvedilol | 124 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 43 |
| Ozempic | Semaglutide | 119 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 50 |
| Farxiga | Dapagliflozin Propanediol | 107 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 102 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 31 |
| Ezetimibe | Ezetimibe | 88 | 31 |
| Jardiance | Empagliflozin | 88 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 88 | 38 |
| Methocarbamol | Methocarbamol | 86 | 33 |
| Famotidine | Famotidine | 85 | 35 |
| Mirtazapine | Mirtazapine | 84 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 83 | 11 |
| Atenolol | Atenolol | 79 | 33 |
| Memantine Hcl | Memantine Hcl | 79 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 79 | 23 |
| Bupropion Xl | Bupropion Hcl | 78 | 20 |
| Fluconazole | Fluconazole | 73 | 54 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 15 |
| Valsartan | Valsartan | 71 | 24 |
| Glipizide | Glipizide | 70 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 38 |
| Prednisone | Prednisone | 68 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 21 |
| Glimepiride | Glimepiride | 65 | 20 |
| Topiramate | Topiramate | 63 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 50 |
| Donepezil Hcl | Donepezil Hcl | 59 | 18 |
| Myrbetriq | Mirabegron | 59 | 16 |
| Fenofibrate | Fenofibrate | 58 | 18 |
| Ibuprofen | Ibuprofen | 58 | 25 |
| Meclizine Hcl | Meclizine Hcl | 57 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 18 |
| Temazepam | Temazepam | 56 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 44 |
| Trulicity | Dulaglutide | 53 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 44 |
| Promethazine Hcl | Promethazine Hcl | 50 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 12 |
| Azithromycin | Azithromycin | 48 | 46 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 34 |
| Glipizide Er | Glipizide | 46 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 16 |
| Synthroid | Levothyroxine Sodium | 46 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 45 | suppressed |
| Estradiol | Estradiol | 45 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 18 |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 16 |
| Diazepam | Diazepam | 39 | 17 |
| Ondansetron Odt | Ondansetron | 39 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | 13 |
| Finasteride | Finasteride | 38 | 12 |
| Nystatin | Nystatin | 38 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 13 |
| Irbesartan | Irbesartan | 37 | 17 |
| Warfarin Sodium | Warfarin Sodium | 37 | 12 |
| Baclofen | Baclofen | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 25 |
| Valacyclovir | Valacyclovir Hcl | 33 | 14 |
| Vraylar | Cariprazine Hcl | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 23 |
| Naproxen | Naproxen | 31 | suppressed |
| Linzess | Linaclotide | 30 | 13 |
| Verapamil Hcl | Verapamil Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 29 | 12 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | 11 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Cephalexin | Cephalexin | 24 | 12 |
| Mupirocin | Mupirocin | 24 | 21 |
| Clonidine | Clonidine | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | 11 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Perphenazine | Perphenazine | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | 12 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $961.51 · 58 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, JATENZO, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error